Baxdrostat shows promise as game-changer for resistant hypertension

High blood pressure that refuses to budge despite multiple medications is a grinding problem for millions of people worldwide. It's one of the leading drivers of heart disease and stroke, and for those whose bodies resist the standard arsenal of drugs, the options have been limited and frustrating. A new experimental medication called Baxdrostat is beginning to change that picture.

The drug emerged from a straightforward observation about how resistant hypertension actually works. When blood pressure stays stubbornly elevated even after patients take three or more medications—including a diuretic—the culprit is often a hormone called aldosterone. This hormone tells the kidneys to hold onto salt and water, which increases blood volume, narrows blood vessels, and drives pressure upward. Baxdrostat takes a different approach than older treatments: instead of blocking aldosterone's effects after the fact, it stops the enzyme that produces aldosterone in the first place. The result is lower aldosterone without disrupting cortisol, the hormone the body needs for managing stress and inflammation.

The clinical evidence comes from a trial called BaxHTN, a global randomized study published in The New England Journal of Medicine. Researchers enrolled adults whose systolic blood pressure remained between 140 and 170 millimeters of mercury despite standard treatment. Some had failed to control their pressure on two medications; others had resisted three or more, including a diuretic. Over twelve weeks, participants received either a placebo or Baxdrostat at doses of 1 milligram or 2 milligrams, added on top of their existing therapy.

The results were substantial. The 1-milligram dose lowered systolic pressure by 8.7 millimeters of mercury compared to placebo, while the 2-milligram dose achieved a 9.8-millimeter drop. These gains came on top of medications patients were already taking—a crucial detail for people whose medicine cabinets are already full. Bryan Williams, the study's lead investigator and chair of medicine at University College London, called the reduction "exciting," noting that even these modest-sounding numbers translate into meaningfully lower risk of heart attack, stroke, heart failure, and kidney disease over time.

The safety profile matters as much as the efficacy. Any drug that lowers aldosterone carries the risk of raising potassium levels, and the BaxHTN data confirmed this risk exists. With the 1-milligram dose, confirmed hyperkalemia—potassium above 6.0 millimoles per liter—occurred in 2.3 percent of patients. The 2-milligram dose saw 3.0 percent. The placebo group experienced 0.4 percent. Most cases were manageable through routine monitoring and dose adjustments, a familiar approach for doctors already tracking potassium in patients on ACE inhibitors or certain diuretics. The difference between Baxdrostat and older mineralocorticoid receptor blockers is that those older drugs often caused more severe potassium problems and other side effects; this new approach is more targeted and gentler.

For patients who have spent years fighting their own blood pressure, the implications are significant. Resistant hypertension is not rare. It affects millions globally, and for many of them, existing options have been exhausted or poorly tolerated. Baxdrostat could be especially valuable for people whose aldosterone levels are driving their hypertension, or those who have struggled with the side effects of high-dose mineralocorticoid receptor blockers. Some evidence suggests it may also help with nighttime blood pressure surges, which are often linked to aldosterone activity.

For now, Baxdrostat remains experimental, available only within clinical trials. Regulatory approval is still ahead. But if it clears those hurdles, the drug has the potential to reshape how doctors approach one of medicine's most stubborn problems—giving real hope to patients who have long felt trapped by their own physiology.